Galapagos NV is a Belgium-based biopharmaceutical company focused on discovering and developing small‑molecule medicines and cell therapies for immune-related diseases and cancer. Founded in 1999 and headquartered in Mechelen, it conducts R&D and clinical programs primarily in Europe, applying target discovery, medicinal chemistry, process development, and translational biology, alongside emerging decentralized manufacturing approaches for cell therapy.
Galapagos co-developed filgotinib, a selective JAK1 inhibitor marketed as Jyseleca in parts of Europe and Japan for rheumatoid arthritis and, in some regions, ulcerative colitis; the drug is not approved in the United States. The company has expanded into oncology and autologous CAR‑T cell therapies, including a point‑of‑care model enabled by the acquisitions of CellPoint and AboundBio. Galapagos is listed on Euronext Amsterdam and Brussels and on Nasdaq (ticker: GLPG).
None yet. When a new project in the record names Galapagos as owner, partner or investor, it shows here.
Current CEO Christophe Weber will retire at the June 24 shareholder meeting; Bruce Broussard, Koichiro Kimura and Paul Stoffels proposed as new external directors; six existing externals to retire.
